Together, these studies uncover novel compensatory pathways that may be involved ... Key among these is the activation of signaling by RHO (another member of the RAS superfamily) and the up ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming catalysts for ...

As this topic is less discussed in the literature, within this review we focus on the differences among RAS proteins mutations with respect to their preferential signaling pathways, biochemistry, ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

About 20% of patients with RASopathies have HCM; RASopathy-associated HCM is often caused by genetic mutations in the RAS/MAPK signaling pathway, which regulates cell growth and development.

Human cell transformation systems revealed that RAL-GEF signaling is particularly required for oncogenic RAS function in human ... Co-opted pathways required by oncogenic KRAS in order to sustain ...

One of the best studied signalling routes is the mitogen activated protein (MAP) kinase signal transduction pathway which plays a crucial role in many aspects of immune mediated inflammatory responses ...

Our pipeline is focused on RAS/MAPK-driven cancers, specifically novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, ...

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...